Shares of Trinity Biotech stock opened at $1.29 on Friday. Trinity Biotech has a one year low of $0.86 and a one year high of $3.66. The stock’s 50-day moving average is $1.13 and its 200 day moving average is $1.32. The firm has a market cap of $34.72 million, a price-to-earnings ratio of 14.33 and a beta of 1.33.
Trinity Biotech (NASDAQ:TRIB – Get Rating) last announced its earnings results on Monday, April 11th. The company reported $0.06 EPS for the quarter. Trinity Biotech had a negative return on equity of 27,745.46% and a net margin of 0.94%. The company had revenue of $19.53 million for the quarter.
Trinity Biotech Company Profile (Get Rating)
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Zoom Video Communications Is Primed To Launch Higher
- Institutions Buy The Dip In Petco Health and Wellness Company
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Veeva Systems: Increasing NDR and Other Wins
- Autozone Edges Past Advanced Auto Parts In Q1 2022
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.